Survival benefit of boron neutron capture therapy for recurrent malignant gliomas

Applied Radiation and Isotopes

Volumn 67, Issue 7-8 SUPPL., 2009, Pages

  Miyatake, Shin Ichi ^a   Kawabata, Shinji ^a   Yokoyama, Kunio ^a   Kuroiwa, Toshihiko ^a   Michiue, Hiroyuki ^b   Sakurai, Yoshinori ^c   Kumada, Hiroaki ^d   Suzuki, Minoru ^c   Maruhashi, Akira ^c   Kirihata, Mitsunori ^e   Onoc, Koji ^c  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d JAPAN ATOMIC ENERGY AGENCY   (Japan)

^e Osaka Prefecture University   (Japan)

Author keywords

Boronophenylalanine PET; Glioblastoma; Malignant glioma; Recursive partitioning analysis (RPA)

Indexed keywords

BORON NEUTRON CAPTURE THERAPY; BORONOPHENYLALANINE PET; BRAIN TUMORS; CLASSIFICATION ,; GLIOBLASTOMA; MALIGNANT GLIOMA; MEDIAN SURVIVAL TIME; RECURSIVE PARTITIONING ANALYSIS; RECURSIVE PARTITIONING ANALYSIS (RPA); SURVIVAL TIME;

BORON; BORON COMPOUNDS; RECURSIVE FUNCTIONS;

REGRESSION ANALYSIS;

4 BORONOPHENYLALANINE; BOROCAPTATE; TEMOZOLOMIDE;

ADOLESCENT; ADULT; ARTICLE; CANCER RELAPSE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; GLIOBLASTOMA; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; MALE; NEUTRON CAPTURE THERAPY; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; SURVIVAL TIME;

ADOLESCENT; ADULT; AGED; BORON NEUTRON CAPTURE THERAPY; BRAIN NEOPLASMS; FEMALE; GLIOBLASTOMA; GLIOMA; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RISK FACTORS; YOUNG ADULT;

EID: 67649389423     PISSN: 09698043     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.apradiso.2009.03.032     Document Type: Article

References (5)

1. Brada M., Hoang-Xuan K., Rampling R., Dietrich P.Y., Dirix L.Y., Macdonald D., et al. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann. Oncol. 12 (2001) 259-266
2. Carson K.A., Grossman S.A., Fisher J.D., and Shaw E.G. Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials. J. Clin. Oncol. 25 (2007) 2601-2606
3. Pellettieri L., Stenstam B.H., Rezaei A., Giusti V., and Skold K. An investigation of boron neutron capture therapy for recurrent glioblastoma multiforme. Acta Neurol. Scand. 117 (2008) 191-197
4. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352 (2005) 987-996
5. Wong E.T., Hess K.R., Gleason M.J., Jaeckle K.A., Kyritsis A.P., Prados M.D., et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J. Clin. Oncol. 17 (1999) 2572-2578